Group 1 - Tsinghua Dongbao (600867.SH) reported its Q3 2025 results, with 9 institutional investors holding a total of 928 million shares, representing 47.39% of the total share capital [1] - The institutional holding ratio increased by 0.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely the Innovative Medicine fund, increased its holdings slightly, while two funds, including the China Securities National Biomedicine Index A and Southern CSI 500 ETF, reduced their holdings by 0.17% [2] - A total of 249 public funds did not disclose their holdings this period, including Tianhong National Biomedicine ETF and Guotai CSI Biomedicine ETF [2] Group 3 - MACD golden cross signals have formed, indicating a positive trend for certain stocks [3]

Core Viewpoint - Yiqiao Shenzhou (301047.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in fund holdings [1][2] Institutional Ownership - As of October 27, 2025, a total of 10 institutional investors disclosed holdings in Yiqiao Shenzhou A-shares, with a combined holding of 75.024 million shares, representing 61.68% of the total share capital [1] - The top ten institutional investors include various management consulting partnerships and investment firms, with their combined holding percentage decreasing by 0.74 percentage points compared to the previous quarter [1] Public Fund Holdings - In this reporting period, 46 public funds were not disclosed compared to the previous quarter, including notable funds such as Dachen Rui Xiang Mixed A and Southern CSI 1000 ETF [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.16% compared to the previous period [2]

Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business areas include drug research, development, and production services, with revenue composition as follows: laboratory services 60.43%, CMC (small molecule CDMO) services 21.58%, clinical research services 14.58%, macromolecule and cell and gene therapy services 3.28%, and others 0.12% [1] Stock Performance - On September 18, Kanglong Chemical's stock rose by 5.38%, reaching a price of 37.40 CNY per share, with a trading volume of 1.849 billion CNY and a turnover rate of 3.63%. The total market capitalization is 66.505 billion CNY [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under China Merchants Fund holds a significant position in Kanglong Chemical. The fund, China Merchants National Bio-Medical Index A (161726), reduced its holdings by 772,800 shares in the second quarter, retaining 15.765 million shares, which accounts for 4.22% of the fund's net value, ranking it as the seventh-largest heavy stock [2] - The fund has a total scale of 7.519 billion CNY and has achieved a return of 24.26% year-to-date, ranking 2223 out of 4222 in its category. Over the past year, the return is 45.43%, ranking 2450 out of 3804, while since its inception, it has incurred a loss of 25.67% [2] Fund Management - The fund manager for China Merchants National Bio-Medical Index A is Hou Hao, who has been in the position for 8 years and 30 days, managing assets totaling 55.459 billion CNY, with the best fund return during his tenure being 758.66% and the worst being -58.37% [3] - Co-manager Xu Rongman has been in the role for 4 years and 179 days, overseeing assets of 27.361 billion CNY, with the best return of 67.05% and the worst also at -58.37% during his tenure [3]

Group 1 - The core viewpoint of the news is that Jianfan Bio (300529.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 51.87 million shares held by six institutions, representing 6.49% of the total share capital, down by 2.00 percentage points from the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, including Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with an increase ratio of 0.25% [2] - Two public funds decreased their holdings, namely, Zhaoshang Guozhen Biomedical Index A and Yifangda Growth Enterprise ETF, with a decrease ratio of 0.11% [2] - Six public funds did not disclose their holdings in the current period, including Guangda Baodexin Credit Enhancement Bond A and others [2] Group 3 - Regarding foreign investment, the Hong Kong Central Clearing Limited is noted as an institution that did not disclose its holdings in the current period [3]

Group 1 - Wante Bio (603392.SH) released its 2024 annual report on April 12, 2025, indicating that as of April 11, 2025, 219 institutional investors disclosed holding A-shares of Wante Bio, totaling 778 million shares, which accounts for 61.50% of the total share capital [1] - The top ten institutional investors include companies such as Yangshengtang Co., Ltd., Hong Kong Central Clearing Limited, and various ETFs, with the top ten collectively holding 60.17% of the shares, a decrease of 0.29 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 22 funds increased their holdings compared to the previous period, with a total increase of 0.16%, including funds like Innovation Drug and Tianhong National Medicine ETF [2] - Conversely, 6 public funds reduced their holdings, with a total decrease of 0.11%, including funds such as Huatai-PB CSI 300 ETF and Morgan CSI Innovation Drug Industry ETF [2] - A total of 189 new public funds were disclosed this period, including major ETFs like E Fund CSI 300 Medicine ETF and Huaxia CSI 300 ETF [2]

Group 1 - Rongchang Biologics (688331.SH) released its 2024 annual report on March 28, 2025, indicating that as of March 27, 2025, 29 institutional investors disclosed holding a total of 214 million shares, accounting for 39.31% of the total share capital [1] - The top ten institutional investors include Yantai Rongda Venture Capital Center (Limited Partnership), Yantai Rongqian Enterprise Management Center (Limited Partnership), and others, with a combined holding ratio of 36.29%, showing a slight decrease of 0.04 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, including Huatai-PineBridge Medical Service Flexible Allocation Mixed A and Huatai-PineBridge Daxin Mixed A, with an increase ratio of 0.38% [2] - Two public funds reduced their holdings, including Bank of China Innovation Medical Mixed A and Rongtong Vision Value One-Year Holding Period Mixed A, showing a slight decline [2] - Three new public funds were disclosed this period, including China Merchants National Index Biomedicine A, Tianzhi New Consumption Mixed, and Zhongtai CSI 500 Index Enhanced A [2] - Twenty-one public funds were not disclosed this period, including E Fund Healthcare Industry Mixed A and Bank of China Healthcare Mixed A [2]

Group 1 - The core viewpoint of the news is that as of March 27, 2025, institutional investors hold a significant portion of Tiger Medical's A-shares, totaling 1.76 billion shares, which accounts for 20.31% of the company's total equity [1] - The top ten institutional investors collectively hold 14.86% of Tiger Medical's shares, with a decrease of 1.43 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, while five funds decreased their holdings, with a total reduction rate of 0.19% [2] - A total of 16 new public funds were disclosed this period, including notable funds such as E Fund CSI 300 Medical ETF and others [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.30% compared to the previous quarter [2]